Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007. - sprookjes - yvandenbroek - TriplyDB

Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007.

Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007.

http://www.wikidata.org/entity/Q33577145

about

Multidrug resistance: an emerging crisis TB vaccine development and the End TB Strategy: importance and current status.Drug-resistant TB: deadly, costly and in need of a vaccine Estimating tuberculosis cases and their economic costs averted in the United States over the past two decades Use of Transnational Services to Prevent Treatment Interruption in Tuberculosis-Infected Persons Who Leave the United States The effect of early versus late treatment initiation after diagnosis on the outcomes of patients treated for multidrug-resistant tuberculosis: a systematic review Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014 Cost-optimization in the treatment of multidrug resistant tuberculosis in Nigeria.Access to Bacteriologic-Based Diagnosis in Smear Positive Retreatment Tuberculosis Patients in Rural China: A Cross-Sectional Study in Three Geographic Varied Provinces.Hospital costs in the US for pulmonary mycobacterial diseases.Tuberculosis Elimination Efforts in the United States in the Era of Insurance Expansion and the Affordable Care Act.Resistant tuberculosis in Maranhão, Brazil: a case series.Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.Does Alcohol consumption during multidrug-resistant tuberculosis treatment affect outcome?. A population-based study in Kerala, India Tuberculosis hospitalization expenditures per patient from private health insurance claims data, 2010-2014.A cost-benefit analysis of a proposed overseas refugee latent tuberculosis infection screening and treatment program.Cathepsin K Contributes to Cavitation and Collagen Turnover in Pulmonary Tuberculosis Characteristics and costs of multidrug-resistant tuberculosis in-patient care in the United States, 2005-2007.Delayed and Unreported Drug-Susceptibility Testing Results in the US National Tuberculosis Surveillance System, 1993-2014.Review of nucleic acid amplification tests and clinical prediction rules for diagnosis of tuberculosis in acute care facilities.A systematic synthesis of direct costs to treat and manage tuberculosis disease applied to California, 2015.Epidemiological trends and outcomes of extensively drug-resistant tuberculosis in Shandong, China Design, synthesis and evaluation of indole-2-carboxamides with pan anti-mycobacterial activity.Epidemiology of pediatric multidrug-resistant tuberculosis in the United States, 1993-2014.Genitourinary Presentation of Tuberculosis.Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia.Prevalence and risk factors of multi-drug resistant tuberculosis in Dalian, China.Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.Outcomes and costs of out-patient MDR-TB care in the USA.Serial testing for latent tuberculosis using QuantiFERON-TB Gold In-Tube: A Markov model.Fluoroquinolone Therapy for the Prevention of Multidrug-Resistant Tuberculosis in Contacts. A Cost-Effectiveness Analysis.Tuberculosis Patients Who Are A Potential Source for Unprotected Exposure in Health Care Systems: A Multicenter Case Control Study.Factors Associated With All-Cause Mortality Among Patients With Multidrug-Resistant Tuberculosis-United States, 1993-2013.Efficacy and Safety of Vitamin D Supplementation for Pulmonary Tuberculosis: A Systematic Review and Meta-analysis.Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection.The California Multidrug-Resistant Tuberculosis Consult Service: a partnership of state and local programs.Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill.The relative fitness of drug-resistant : a modelling study of household transmission in Peru New Ways to Treat Tuberculosis Using Dendrimers as Nanocarriers Management of rifampicin mono-resistant tuberculosis in Queensland, Australia: a retrospective case series

P2860

Q21284693-8E28F69B-7306-4C13-88D7-7CC73A79DDF5 Q26748621-4E17F02A-B8C7-4CF4-8E5D-909783F32684 Q26765385-ABBB5195-853D-4DE7-905A-69F21C02ABA9 Q28387169-C186F374-03B0-4F06-8911-797B7D8AAFD3 Q28387933-B8F8CDE9-54BE-4F51-94FE-2EFF39ED526B Q28551772-EDE42FC7-6FDD-4C62-9ECF-3B1E7F1498EA Q30300207-B896E15C-B0C3-4E5C-B142-A9045D629AAF Q30488596-BCA43A0F-1449-4B01-A957-683BD2B51444 Q35890064-BD824AA4-C760-455F-A025-2FD194DBFADA Q35915261-43C33213-F431-40B9-9E92-76DA5602A9AA Q35990818-13F003D2-85CF-4102-8971-B47421B753B4 Q36008537-E9665C65-59E4-4BDD-AB5E-EB878447E4D8 Q36024119-F090F2E5-713E-4AA0-BBC2-6CDB1C27E21C Q36244615-EFA4463F-45B8-4D1A-85E3-08822A5B04D5 Q36305207-682880CC-1B86-4692-8210-AB7F5A3FBDBC Q36337142-3BC0A915-F33A-423D-8523-81909FC46949 Q36487876-E2564C7E-6581-44EA-89C4-F3224AE38A4B Q36800645-32F1A1C3-3176-4703-9197-D57FD61CE2E5 Q38400633-C68376C5-7262-4528-BE83-39EEAD955E68 Q38545695-0520C0A6-C035-4604-9C7B-ADBB19D02416 Q38601841-81BB737B-528A-4B8D-958E-F9FB57E4F15C Q38644773-FE579ECC-1189-4F8A-B215-7007C1A57A77 Q38702237-A1A53B72-BC00-490B-AE9A-264C46E84F3D Q38716840-6FAA2C2C-31EA-41BD-A8A7-785D0376B119 Q38843907-16E115E1-96BB-43A0-8F1C-794B7BCC229C Q38868135-910A1D74-A192-4DCA-AEF3-3C1C60B0714C Q38874630-046A76BC-57F7-494A-A039-495AFCC93095 Q38886442-A515BB39-C06F-4AB5-A3FD-47BBCAC18872 Q40298429-492B719D-130F-41AA-89E3-7ACE0B6BD6D1 Q40596209-2D7B0F9B-71BE-493A-A688-8E69D06FD433 Q41009954-053705DE-5F77-4F16-90AA-AAD7CDF24C66 Q47133822-6B7ACE65-BF01-443F-85CF-16EBB861F281 Q47617120-75756B48-2241-4FE5-B18F-B296DCFEBE26 Q55279948-C3AE0428-C57C-406F-BD41-9B6135775611 Q55407610-2AE09754-F367-468D-970D-AA0F9EE77F3F Q55419989-610389D4-2487-44A2-A1E5-FD19D2B6BE8F Q55547799-6685B05A-5B86-4BEC-9963-F709CC7BBBA9 Q56895151-8617BAB3-5F5F-4465-B1FF-B557FD501A88 Q57174607-47257FE5-E473-416A-AC1F-FE3DBBD2281F Q58741073-18E1B255-D65F-4D1B-B76C-39132BC1C6E5

P2860

Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007.

http://www.wikidata.org/entity/Q33577145

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Treatment practices, outcomes, ...... sis, United States, 2005-2007.

@ast

Treatment practices, outcomes, ...... sis, United States, 2005-2007.

@en

Treatment practices, outcomes, ...... sis, United States, 2005-2007.

@nl

type

label

Treatment practices, outcomes, ...... sis, United States, 2005-2007.

@ast

Treatment practices, outcomes, ...... sis, United States, 2005-2007.

@en

Treatment practices, outcomes, ...... sis, United States, 2005-2007.

@nl

prefLabel

Treatment practices, outcomes, ...... sis, United States, 2005-2007.

@ast

Treatment practices, outcomes, ...... sis, United States, 2005-2007.

@en

Treatment practices, outcomes, ...... sis, United States, 2005-2007.

@nl

P1433

Q33577145-50AA2ECA-079C-4CC2-922D-7E02C825508A

P1476

Q33577145-24109669-B1E1-4AD8-9CEA-9723F4C53592

P2093

Q33577145-1C222024-F118-4D25-8847-562CEE34B952

Q33577145-29E24C7D-63B8-49EA-9CF7-6F94C6006CC3

Q33577145-2F144B25-0FA9-4D43-8215-878977E7D388

Q33577145-339ED9C8-4CDB-4809-8B78-917BFA00FAD7

Q33577145-3BA0F9A9-47AD-440D-AF3A-FF11D293C105

Q33577145-461CB53A-B8D1-42E4-9DF4-82D91B166B14

Q33577145-4C8D04DF-FE58-4C07-B0A0-1B0CF1E1F3C0

Q33577145-5783C206-FDE7-4931-9AB8-753F04109682

Q33577145-7D9870B9-C8B8-4023-90DE-E14FEF24ED42

Q33577145-89CD9C98-4B86-402B-A965-9C2DC4C35780

P2860

Q33577145-0729EDE5-058A-41A3-810A-188F8B80FB68

Q33577145-15C0BF47-E109-4A57-8E61-0A04BB37A6C5

Q33577145-16D260C0-F4B8-4BD9-8E68-5DD8F78937FE

Q33577145-1D31F2EA-1807-4CD8-A902-4BF3BFC2CC26

Q33577145-39A1EEDA-E6CB-46AA-ADE1-455B45D2E2FA

Q33577145-40BEBA2E-5042-4C31-BB99-C75E68D29467

Q33577145-5BBD22E1-3869-44D8-91FA-DB510994416C

Q33577145-5D0E6022-476E-4664-9B28-47D1293B73E2

Q33577145-5DEB52F1-BD4F-4BC1-85A6-579C6F8B9555

Q33577145-79CC395A-2610-4981-B967-3C466F749707

P304

Q33577145-202B1B16-3366-41FF-A8C7-5747E06033FC

P31

Q33577145-3B1ABEE8-7E74-4E4E-8758-7CD195A1D3DB

P356

Q33577145-D85D596A-F09C-4FAD-BD74-5AD244EC48BD

P433

Q33577145-BFBB0E91-4E9E-4183-9008-FA0E55E429DD

P478

Q33577145-AB51B9E4-95F4-492C-9312-522E15D2179F

P577

Q33577145-143D3AB4-8056-4E92-81ED-E7A2EF85E804

P5875

Q33577145-D7905C5E-6F47-4A73-8BFE-CF49D0FBCAA4

P698

Q33577145-FFFC87DD-DD82-49D3-BD0E-FC950F1A0B11

P921

Q33577145-1A363DE1-3048-43A2-9B71-AC1C196FEA3E

Q33577145-4166999C-5983-472F-B363-64981CA68AA0

Q33577145-87A0037A-07AC-4FF9-8D05-4C9914FC0A12

P932

Q33577145-6729013A-8870-4159-B213-4A8559355524

P356

P1433

Emerging Infectious Diseases

P1476

Treatment practices, outcomes, ...... sis, United States, 2005-2007.

@en

P2093

Barbara Seaworth

http://www.w3.org/2001/XMLSchema#string

Edward A Graviss

http://www.w3.org/2001/XMLSchema#string

Jennifer Flood

http://www.w3.org/2001/XMLSchema#string

Kathryn Sheeran

http://www.w3.org/2001/XMLSchema#string

Katya Salcedo

http://www.w3.org/2001/XMLSchema#string

Lisa Armitige

http://www.w3.org/2001/XMLSchema#string

Lori Armstrong

http://www.w3.org/2001/XMLSchema#string

Manuel Revuelta

http://www.w3.org/2001/XMLSchema#string

Paul W Colson

http://www.w3.org/2001/XMLSchema#string

Peter Oh

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study

Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis

Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients

Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis

Costs of patients hospitalized for multidrug-resistant tuberculosis.

Tuberculosis in New York City--turning the tide.

Rapid drug susceptibility testing with a molecular beacon assay is associated with earlier diagnosis and treatment of multidrug-resistant tuberculosis in California

Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.

The costs of treating breast cancer in the US: a synthesis of published evidence.

Public-private collaboration for multidrug-resistant tuberculosis control in New York City.

P304

812-821

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3201/EID2005.131037

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261769063

http://www.w3.org/2001/XMLSchema#string

P698

24751166

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

Ameeriga Ütisriigiq

multiple drug resistance

P932

4012799

http://www.w3.org/2001/XMLSchema#string